Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $69.71 in the prior trading day, Axsome Therapeutics Inc (NASDAQ: AXSM) closed at $65.72, down -5.72%. In other words, the price has decreased by -$5.72 from its previous closing price. On the day, 0.83 million shares were traded. AXSM stock price reached its highest trading level at $70.0775 during the session, while it also had its lowest trading level at $65.6065.
Ratios:
Our goal is to gain a better understanding of AXSM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.52 and its Current Ratio is at 3.63. In the meantime, Its Debt-to-Equity ratio is 0.98 whereas as Long-Term Debt/Eq ratio is at 0.97.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on March 19, 2024, initiated with a Outperform rating and assigned the stock a target price of $108.
On February 06, 2024, UBS started tracking the stock assigning a Buy rating and target price of $111.
On January 25, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $126.RBC Capital Mkts initiated its Outperform rating on January 25, 2024, with a $126 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 01 ’24 when Jacobson Mark L. sold 24,662 shares for $77.24 per share. The transaction valued at 1,904,942 led to the insider holds 0 shares of the business.
JEFFS ROGER sold 2,347 shares of AXSM for $168,062 on Mar 15 ’24. The Director now owns 120,756 shares after completing the transaction at $71.61 per share. On Mar 14 ’24, another insider, JEFFS ROGER, who serves as the Director of the company, sold 29,976 shares for $69.70 each. As a result, the insider received 2,089,387 and left with 120,756 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AXSM now has a Market Capitalization of 3113445632 and an Enterprise Value of 2913623040. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.50 while its Price-to-Book (P/B) ratio in mrq is 16.29. Its current Enterprise Value per Revenue stands at 10.767 whereas that against EBITDA is -15.97.
Stock Price History:
Over the past 52 weeks, AXSM has reached a high of $98.40, while it has fallen to a 52-week low of $55.02. The 50-Day Moving Average of the stock is -16.82%, while the 200-Day Moving Average is calculated to be -12.22%.
Shares Statistics:
The stock has traded on average 724.47K shares per day over the past 3-months and 544400 shares per day over the last 10 days, according to various share statistics. A total of 47.35M shares are outstanding, with a floating share count of 38.78M. Insiders hold about 18.14% of the company’s shares, while institutions hold 80.85% stake in the company. Shares short for AXSM as of 1711584000 were 7650712 with a Short Ratio of 10.56, compared to 1709164800 on 7470339. Therefore, it implies a Short% of Shares Outstanding of 7650712 and a Short% of Float of 19.440001000000002.
Earnings Estimates
Axsome Therapeutics Inc (AXSM) is presently subject to a detailed evaluation by Axsome Therapeutics, Inc. analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.74, with high estimates of $20.41 and low estimates of $61.47.
